Retina Society 2024: Companies announce presentations ahead of 57th Annual Meeting

(Image Credit: AdobeStock/smallredgirl)

The Retina Society is set to host their 57th annual Scientific Meeting in Lisbon, Portugal from September 11-15, 2024. The meeting will showcase a scientific program “designed to facilitate discussion and exchange of ideas and social functions which will allow [attendees] to reconnect with one another.”

Other than allowing attendees to reconnect, they will be able to hear updates on new and ongoing studies and data from leading companies across the world. With the meeting set to begin soon, companies have started to announce their participation in the meeting and what some of the data presented will focus on.

Below is a non-exhaustive list (in alphabetical order) of companies and the information surrounding their Retina Society presentations.

4D Molecular Therapeutics

4DMT will present interim results from the PRISM phase 1/2 clinical trial evaluating intravitreal 4D-150. This potential treatment is being evaluated for adults with neovascular age-related macular degeneration (nAMD).¹

The presentation, titled “Interim Results from the PRISM Phase 1/2 Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration” will take place on Sunday, September 15, 2024, at 8:34-8:39 am CEST. It will be presented by David Eichenbaum, MD, FASRS, director of research, Retina Vitreous Associates of Florida, St Petersburg, FL.¹

Annexon Biosciences

Annexon Biosciences will present analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA).

The presentation, titled “Preservation of Photoreceptors and Prevention of Visual Acuity Loss by ANX007 in Geographic Atrophy (GA) in the Phase 2 ARCHER Trial” will take place on Saturday, September 14, 2024 at 10:28 am CEST. It will be presented by Glenn J. Jaffe, MD, Duke Department of Ophthalmology, North Carolina, US.²

Ocular Therapeutix

Andrew A. Moshfeghi, MD, MBA, Vice Chair; Medical Director, University of Southern California Roski Eye Institute will have an oral presentation on behalf of Ocular Therapeutix titled “52-week Rescue-Free Subjects Treated with Axitinib Hydrogel Implant (OTX-TKI) in the US Phase 1 Clinical Trial for Neovascular Age-Related Macular Degeneration.” The presentation will take place Friday, September 13, 8:48 AM – 8:55 AM (CEST).³

ONL Therapeutics

ONL Therapeutics announced a pair of presentations at the Retina Society around FAS inhibition. The first will take place at 11:44 am (CEST) on Saturday, September 14, 2024, and be presented by Lejla Vajzovic, MD, Associate Professor of Ophthalmology, Duke University Eye Center. Vajzovic will present on “Fas Inhibition with ONL1204 for the Treatment of Geographic Atrophy: Results from a Phase 1b Study.”⁴

The second presentation will take place at 1:46 pm (CEST) on Saturday, September 14, 2024. Durga Borkar, MD, MMCi, Associate Professor of Ophthalmology, Duke University Eye Center, will present “FAS Inhibition with Intravitreal ONL1204 for the Treatment of Macula-off Rhegmatogenous Retinal Detachment: Results from a Phase 2 Study.”⁴

References:

1. 4DMT Announces Presentations at Upcoming Retina Conferences. 4D Molecular Therapeutics. Published September 5, 2024. Accessed September 10, 2024. https://www.globenewswire.com/en/news-release/2024/09/05/2941291/0/en/4DMT-Announces-Presentations-at-Upcoming-Retina-Conferences.html

2. Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress. Annexon Biosciences. Published September 9, 2024. Accessed September 10, 2024. https://www.globenewswire.com/en/news-release/2024/09/09/2942770/0/en/Annexon-to-Present-Phase-2-ARCHER-Data-on-Protection-of-Vision-and-Photoreceptors-with-ANX007-in-GA-at-the-Retina-Society-57th-Annual-Meeting-and-24th-Euretina-Congress.html

3. Ocular Therapeutix™ to Present at September Retina Meetings. Ocular Therapeutix. Published September 5, 2024. Accessed September 10, 2024. https://www.globenewswire.com/en/news-release/2024/09/05/2941241/0/en/Ocular-Therapeutix-to-Present-at-September-Retina-Meetings.html

4. ONL Therapeutics to Present at the 57th Annual Scientific Meeting of The Retina Society and EURETINA Innovation Spotlight. ONL Therapeutics. Published September 10, 2024. Accessed September 10, 2024. https://www.globenewswire.com/en/news-release/2024/09/10/2943524/0/en/ONL-Therapeutics-to-Present-at-the-57th-Annual-Scientific-Meeting-of-The-Retina-Society-and-EURETINA-Innovation-Spotlight.html